




“Patients will now be able to complete a non-invasive treatment that could help improve their vision earlier in the disease process.”



The LIGHTSITE III clinical trial evaluated the safety and effectiveness of photobimodulation (PBM) therapy for treating non-neovascular (dry) age related macular degeneration (AMD).

Conducted across ten U.S. retinal centers, the study enrolled 100 participants with early to intermediate dry AMD, who received PBM treatments every four months within a 24 month period.

Schedule Your Appointment Today!

Phone: (262) 421-4412


www.northshore-eye.com



NORTH SHORE
EYE HEALTH & WELLNESS

FOR VISION • FOR HEALTH • FOR LIFE

**Low Level Light
Therapy for
Dry Macular
Degeneration**



What is Photobiomodulation?

Photobiomodulation (**PBM**) is a novel concept in treating retinal disease. It involves using a device to deliver **low-level light** to specific areas of the retina to stimulate cellular response.

Three specific wavelengths are used to stimulate healthful cellular function: 590nm, 660nm, and 850nm.


- **590nm (yellow)** inhibits vascular endothelial growth factor expression and removes cellular deposits.
- **660nm (red)** promotes oxygen binding and stimulates adenosine triphosphate (ATP), which inhibits inflammation and cellular loss
- **850nm (infrared)** stimulates metabolic activity as well as ATP, inhibits inflammation cellular loss and drives electron transfer.



Visual Acuity Findings

The primary endpoint was a statistically significant enhancement in best corrected visual acuity in the PBM group compared to the control group.

- **55%** of these PBM subjects gained more than 5 letters, with an average improvement
- **26%** gained over 10 letters, averaging 12.8 letter
- **5.5%** gained over 15 letters of improvement in best corrected visual acuity.



Treatment Details

Our PBM Treatment protocol models the **LIGHTSITE III** design and will be performed as follows:

- Baseline Exam with Photos and Optical Coherence Tomography
- Two PBM Treatments/week for the first four weeks
- Follow by One PBM Treatment/week for the next two months
- Follow-up Exams will attempt to determine how frequent PBM treatments are needed to maintain results.

Our PBM therapy lasts roughly 20 minutes and is well-tolerated with no major side effects reported, making it a safe option for long-term management of dry AMD.



Disease Progression

PBM-treated subjects demonstrated no significant increase in Drusen pathology at 13 months compared to baseline while sham subjects continued to see increases in drusen disposition.

Five of 55 sham eyes progressed to new Geographic Atrophy (GA) (9.1%) versus only 1 of 93 PBM eyes progressed to new GA (1.1%).